Mixed amylin activity compounds

Details Mixed amylin activity compounds Mixed amylin activity compounds

2005-08-30

2005-08-30

Celsa, Bennett (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S866000, C530S324000

Reexamination Certificate

active

06936584

ABSTRACT:
Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.

REFERENCES:
patent: 4758550 (1988-07-01), Cardinaux et al.
patent: 5124314 (1992-06-01), Cooper
patent: 5175145 (1992-12-01), Cooper
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5266561 (1993-11-01), Cooper et al.
patent: 5321008 (1994-06-01), Beaumont et al.
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5376638 (1994-12-01), Young et al.
patent: 5508260 (1996-04-01), Beaumont et al.
patent: 5580953 (1996-12-01), Albrecht et al.
patent: 5625032 (1997-04-01), Gaeta et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5795861 (1998-08-01), Kolterman et al.
patent: WO 92/11863 (1992-07-01), None
patent: WO 93/10147 (1993-05-01), None
patent: WO 93/14408 (1993-07-01), None
patent: WO 95/07098 (1995-03-01), None
Alam et al. Biochem. Biophys. Res. Commun. 179(1):134-139 (1991).
Azria et al., Calcitonins-Physiological and Pharmacological Aspects, pp. 24-25 New York: Springer-Verlag (1989).
Beaumont et al., British Journal of Pharmacology, 115(5):713-715 (1995).
Brain et al., Eur. Journal of Pharmacol., 183:2221 (1990).
Broderick et al., Biochem. Biophys. Res. Comm., 177: 932-938 (1991).
Brown et al., Diabetes 43: 172A Abstract #536 (1994).
Chance et al., Brain Res., 539: 352-354 (1991).
Chantry et al., Biochem. J., 277:139-143 (1991).
Cooper et al., Proc. Natl. Acad. Sci., USA, 84:8628-8632 (1987).
Cooper et al., Proc. Natl. Acad. Sci., 85:7763-7766 (1988).
Fineman et al., Diabetes 40:30A Abstract #0117 (1997).
Follett et al., Clinical Research, 39(1):39A (1991).
Gaeta et al., Med. Chem. Res., 3:483-490 (1990).
Gamse et al., J. of Bone and Mineral Research, 8 (Suppl 1):S200 (1993) Abstract #334.
Gedulin et al., Biochem. Biophys. Res. Commun., 180(2):782-789 (1991).
Gedulin et al., Diabetologia 38 (Suppl 1):A244 Abstract #945 (1995).
Gedulin et al., Metabolism 46(1):67-70 (1997).
Gomez-Foix et al., Biochem J. 276:607-610 (1991).
Huang et al., Hypertension 19:I-101-I-109 (1992).
Jonderko K et al., J. of Clinical Gastroenterology 1990 United States, 12(1), 22-28 (1990).
Koda et al., The Lancet, 339:1179-1180 (1992).
Kolterman et al., Diabetologia, 39:492-499 (1996).
Koopmans et al., Diabetologia, 34:218-224 (1991).
Leighton and Cooper, Nature, 335:632-635 (1988).
Lupien and Young, Diabetes Nutrition and Metabolism-Clinical and Experimental, 6(1) 13-18 (Feb. 1993).
MacDonald et al., Diabetologia, 38(1):118 (1995) (abstract).
Molina et al., Diabetes, 39:260-265 (1990).
Moore et al., Biochem. Biophys. Res. Commun., 179(1):1-9 (1991).
Munson, Anal. Biochem., 107:220-239 (1980).
Nowak et al., J. Lab. Clin. Med., 123(1):110-116 (1994).
Nyholm et al., J. of Clinical Endocrinology and Metabolism, 81(3):1083-1089 (1996).
Ogawa et al., J. Clin. Invest., 85: 973-976 (1990).
Pittner et al., FEBS Letters, 365(1):98-100 (1995).
Pittner et al., J. of Cellular Biochemistry, 55S:19-28 (1994).
Plourde et al., Life Sci., 52:857-862 (1993).
Pozvek, Gordana et al., Molecular Pharmacology, 51(4), 658-665 (1997).
Prickett et al., Petides: Chemistry, Structure and Biology, Proc. of the 14th Am. Peptide Symp., Jun. 1995, Columbus, OH/ed. Kaumaya, P.T.P., Hodges, R.S. pp. 620-622 (1996).
Scarpignato et al., Arch. int. Pharmacodyn. 246:286-294 (1980).
Silvestre et al., Reg. Pegt., 31:23-31 (1990).
Stephens et al., Diabetes, 40:395-400 (1991).
Van Valen et al., Neuroscience Letters, 119:195-198 (1990).
Wang et al., FEBS Lett., 291:195-198 (1991).
Wang et al., Technical Report No. 10, Supp. 42:28 (1988).
Young et al., Current Opinion in Endocrinology & Diabetes, 4(4):282-290 (1997).
Young et al., Mol. Cell. Endocrinol., 84:R1-R5 (1992).
Young et al., Am. J. Physiolog., 263(2):E274-E281 (1992).
Young et al., Am. J. of Physiology, 259:457-461 (1990).
Young et al., Diabetologia, 38:642-648 (1995).
Zaidi et al., Trends in Endocrinology and Metabolism, 4(8):255-259 (1993).
Zhu et al., Biochem. Biophys. Res. Commun., 177(2):771-776 (1991).

Affiliated with

Also associated with

Rating

Mixed amylin activity compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mixed amylin activity compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixed amylin activity compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3453763